The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Scientists are probing woolly mammoth and Neanderthal genetic codes for new compounds as today’s drugs lose potency.

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

A groundbreaking antibiotic discovery might finally tip the balance in the global fight against drug-resistant bacteria.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for ...

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

A live audio webcast of the events will be available online at Events & Presentations. An archived replay of PMV Pharma's presentations will be available for 90 days following the webcast at Events & ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...